SSPN and neoplasm: Both the primary and distant tumor tissues of SPNpro-injected mice exhibited higher MFIs (3.0- and 4.2-fold, respectively) of FITC-labelled anti-granzyme B antibodies than that for SPN-1- or SPN-2-injected mice (Fig. 5b, c, Supplementary Fig. 19).